Sinovac Beefs Up R&D To Bring Vaccines Into Clinical Trials To Prepare For Healthcare Reform
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese vaccine maker Sinovac said it will invest heavily in R&D over the next three years to prepare for China's ongoing healthcare reforms and to reduce the impact of the global financial crisis, during a conference call with investors and analysts on April 9
You may also be interested in...
LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma
SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences
LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma
SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences
Vaccine Market Will Lead Pharmaceutical Industry In China And Globally, Frost & Sullivan Predicts
SHANGHAI - The compound annual growth rate of the global pharmaceutical industry is expected to be around 4-5 percent in the next seven years, while the worldwide vaccine market grows faster, at a CAGR of 14-15 percent, the global business research and consulting firm Frost & Sullivan predicted